

Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation

Policy # 00296

Original Effective Date: 05/18/2011

Current Effective Date: 08/01/2026

Applies to all products administered or underwritten by Blue Cross and Blue Shield of Louisiana and its subsidiary, HMO Louisiana, Inc. (collectively referred to as the "Company"), unless otherwise provided in the applicable contract. Medical technology is constantly evolving, and we reserve the right to review and update Medical Policy periodically.

Investigational or experimental services are not covered. This includes any drug, device, procedure, or service provided under the investigational arm of a clinical trial or clinical study. These services are excluded from coverage under benefits.

Note: Open and Thoracoscopic Approaches to Treat Atrial Fibrillation and Atrial Flutter (Maze and Related Procedures) is addressed separately in medical policy 00624.

Note: Catheter Ablation as Treatment for Atrial Fibrillation is addressed separately in medical policy 00267.

Services Are Considered Investigational

Coverage is not available for investigational medical treatments or procedures, drugs, devices or biological products.

Based on review of available data, the Company considers the use of devices for percutaneous left atrial appendage closure (e.g., Watchman, Amplatzer Amulet, Lariat^{®‡}, Amplatzer Cardiac Plug)^{™‡} for the prevention of stroke in individuals with atrial fibrillation (AF) to be **investigational**.*

Background/Overview

Atrial Fibrillation and Stroke

Atrial fibrillation (AF) is the most common type of irregular heartbeat, affecting at least 2.7 million people in the U.S. Risk of AF has been found to be lower in Black, Hispanic and Asian patients relative to White patients, including following adjustment for demographic and AF risk factors. Stroke is the most serious complication of AF. The estimated incidence of stroke in nontreated patients with AF is 5% per year; despite a lower risk of AF, Black and Hispanic patients have an increased risk of stroke compared with White patients. Stroke associated with AF is primarily embolic, tends to be more severe than the typical ischemic stroke and causes higher rates of mortality and disability. As a result, stroke prevention is a main goal of AF treatment.

Stroke in AF occurs primarily as a result of thromboembolism from the left atrium. The lack of atrial contractions in AF leads to blood stasis in the left atrium, and this low flow state increases the risk for thrombosis. The area of the left atrium with the lowest blood flow in AF, and, therefore, the

Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation

Policy # 00296

Original Effective Date: 05/18/2011

Current Effective Date: 08/01/2026

highest risk of thrombosis is the left atrial appendage (LAA). It has been estimated that 90% of left atrial thrombi occur in the LAA.

Treatment

Pharmacologic

The main treatment for stroke prevention in AF is anticoagulation, which has proven efficacy. The risk for stroke among patients with AF is evaluated using several factors. Two commonly used scores, the CHADS₂ score and the CHA₂DS₂-VASc score are described below in Table 1. Warfarin or newer anticoagulant medications, including dabigatran, rivaroxaban, apixaban, and edoxaban are options for stroke prevention. In nonvalvular AF, newer anticoagulants have demonstrated noninferiority to warfarin in clinical trials. While anticoagulation is effective for stroke prevention, it carries an increased risk of bleeding. Also, warfarin requires frequent monitoring and adjustments as well as lifestyle changes. Newer agents do not require the frequent monitoring seen with warfarin therapy. The 2018 American College of Chest Physicians guidelines (updated from 2012) recommend that CHA₂DS₂VASc be used to evaluate stroke risk, and patients initially identified as having a low stroke risk should not be given antithrombotic therapy. In addition, they recommend bleeding risk assessments be given to every patient at every patient contact and that “potentially modifiable bleeding risk factors” should be the initial focus.

Table 1. CHADS₂ and CHA₂DS₂-VASc Scores to Predict Ischemic Stroke Risk in Patients With Atrial Fibrillation

Letter	Clinical Characteristics	Points Awarded
C	Congestive heart failure (signs/symptoms of heart failure confirmed with objective evidence of cardiac dysfunction)	1
H	Hypertension (resting blood pressure >140/90 mmHg on at least 2 occasions or current antihypertensive pharmacologic treatment)	1
A	Age ≥75 y	1 (CHADS ₂) 2 (CHA ₂ DS ₂ -VASc)
D	Diabetes (fasting glucose >125 mg/dL or treatment with oral hypoglycemic agent and/or insulin)	1
S	Stroke or transient ischemic attack (includes any history of cerebral ischemia)	2
V	Vascular disease (prior myocardial infarction, peripheral arterial disease, or aortic plaque)	1
A	Age 65-74 y	1
Sc	Sex category of female (female sex confers higher risk)	1

Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation

Policy # 00296

Original Effective Date: 05/18/2011

Current Effective Date: 08/01/2026

Adapted from Lip et al (2018) and January et al (2014).

Bleeding is the primary risk associated with systemic anticoagulation. Risk scores have been developed to estimate the risk of significant bleeding in patients treated with systemic anticoagulation, such as the HAS-BLED score, which has been validated to assess the annual risk of significant bleeding in patients with AF treated with warfarin. The score ranges from 0 to 9, based on clinical characteristics, including the presence of hypertension, renal and liver function, history of stroke, bleeding, labile international normalized ratios, age, and drug/alcohol use. Scores of 3 or greater are considered to be associated with a high risk of bleeding, potentially signaling the need for closer monitoring of patients for adverse risks, closer monitoring of international normalized ratios, or differential dose selections of oral anticoagulants or aspirin.

Surgery

Surgical removal, or exclusion, of the LAA is often performed in patients with AF who are undergoing open heart surgery for other reasons. Percutaneous left atrial appendage closure (LAAC) devices have been developed as a nonpharmacologic alternative to anticoagulation for stroke prevention in AF. The devices may prevent stroke by occluding the LAA, thus preventing thrombus formation.

Several versions of LAA occlusion devices have been developed. The PLAATO system (ev3 Endovascular) was the first device to be approved by the FDA for LAA occlusion. The device was discontinued in 2007 for commercial reasons, and intellectual property was sold to manufacturers of the Watchman system. The Watchman Left Atrial Appendage System (Boston Scientific) is a self-expanding nickel titanium device. It has a polyester covering and fixation barbs for attachment to the endocardium. Implantation is performed percutaneously through a catheter delivery system, using venous access and transseptal puncture to enter the left atrium. Transesophageal echocardiography and fluoroscopy are used to guide the procedure. Following implantation, patients receive anticoagulation with warfarin or alternative agents for approximately 1 to 2 months. After this period, patients are maintained on antiplatelet agents (i.e., aspirin and/or clopidogrel) indefinitely. The Watchman FLX device is a next-generation Watchman device that is also FDA-approved for LAAC. This device is based on the design of the Watchman device, is fully recapturable and repositionable, and was made to occlude a wider size range of LAA than the original Watchman device. The Amplatzer cardiac plug (St. Jude Medical), is FDA-approved for closure of atrial septal defects but not for LAAC. A second-generation device developed for the specific indication of LAAC, the Amplatzer Amulet (Abbott), received FDA approval in August 2021. The Amplatzer Amulet consists of a nitinol mesh disc to seal the ostium of the LAA and a nitinol mesh distal lobe, to be positioned within the LAA. The device is preloaded within a delivery sheath. The Percutaneous LAA Transcatheter Occlusion device (ev3) has also been evaluated in research studies but has not received FDA approval.

The Lariat Loop Applicator is a suture delivery device approved by the FDA, intended to close a variety of surgical wounds. It is not specifically approved for LAAC. While the Watchman and other devices are implanted in the endocardium, the Lariat is a non-implant epicardial device.

Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation

Policy # 00296

Original Effective Date: 05/18/2011

Current Effective Date: 08/01/2026

Thrombogenesis in patients with AF may not be limited to the left atrium (LA) and up to 10 % of LA thrombi are not located in the LAA, therefore occluding the LAA may not completely eliminate the risk of embolism and stroke. If LAAO incompletely closes the LAA, there is residual communication between the LAA and left atrium, which is referred to as a residual leak. A large residual leak (defined as ≥ 5 mm) is believed to predispose to thrombus formation.

In September 2021, the FDA sent a letter to healthcare providers indicating that women undergoing percutaneous LAA closure may be at higher risk of adverse procedural outcomes than men. This was based on an analysis of registry data from 49,357 patients who underwent LAA closure with the Watchman device. When adjusted for multiple confounding factors, the study found women were more likely than men to experience any adverse event, major adverse events, and major bleeding. Women also had a significantly higher risk of death (adjusted odds ratio [OR], 2.01; 95% confidence interval [CI], 1.31 to 3.09) but absolute risk was low for both women and men (0.3% vs. 0.1%). In their letter, the FDA stated that they believe the benefits continue to outweigh the risks for approved LAA closure devices when used in accordance with their instructions for use.

Outcome Measures

The optimal study design for evaluating the efficacy of percutaneous LAAC for the prevention of stroke in AF is a randomized controlled trial (RCT) that includes clinically relevant measures of health outcomes. The rate of ischemic stroke during follow-up is the primary outcome of interest, along with rates of systemic embolization, cardiac events, bleeding complications, and death. For the LAAC devices, the appropriate comparison group could be oral anticoagulation, no therapy (for patients who have a prohibitive risk for oral anticoagulation), or open surgical repair.

Ideally, percutaneous LAAC devices would represent an alternative to oral anticoagulation for the prevention of stroke in patients with AF. However, during the post implantation period the LAAC device may be associated with increased thrombogenicity, therefore, anticoagulation is used during the periprocedural period. Patients who cannot tolerate even short-term antithrombotic therapy (anticoagulation therapy or dual antiplatelet therapy [aspirin plus a P2Y₁₂ inhibitor such as clopidogrel]) are not ideally suited for LAAO.

TEE is typically done between one and six months post procedure. Device-related thrombus and/or peri device leak ≥ 5 mm may be indications for continued anticoagulation. If the TEE demonstrates that the LAA is completely occluded and long-term anticoagulation is contraindicated, only aspirin is continued indefinitely. If any leak is present postsurgical LAAO, oral anticoagulation should be continued. Severe complications are rare but include pericardial effusion/tamponade, vascular injury, device erosion or embolization, stroke, cardiac arrest, and death.

Most studies evaluating percutaneous LAAC devices have included patients who are eligible for anticoagulation.

Policy # 00296

Original Effective Date: 05/18/2011

Current Effective Date: 08/01/2026

FDA or Other Governmental Regulatory Approval

U.S. Food and Drug Administration (FDA)

In 2002, the PLAATO system (ev3 Endovascular) was the first device to be approved by the FDA for LAA occlusion. The device was discontinued in 2007 for commercial reasons, and intellectual property was sold to manufacturers of the Watchman system.

In 2015, the Watchman^{TM†} Left Atrial Appendage Closure Technology (Boston Scientific) was approved by the FDA through the premarket approval process by the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients with Atrial Fibrillation RCT (PROTECT AF). In 2020, the Watchman FLX device (Boston Scientific) was approved by the FDA based on the single-arm, nonrandomized PINNACLE FLX study.

The Amplatzer^{TM†} Amulet^{TM†} Left Atrial Appendage Occluder (Abbott) received FDA approval in 2021 through the premarket approval process based on results from the Amplatzer Amulet Left Atrial Appendage Occluder Randomized Controlled Trial (Amulet IDE Trial). The Watchman and Amplatzer Amulet devices are indicated to reduce the risk of thromboembolism from the LAA in individuals with nonvalvular AF who:

- Are at increased risk for stroke and systemic embolism based on CHADS₂ or CHA₂DS₂-VASc scores and are recommended for anticoagulation therapy;
- Are deemed by their physicians to be suitable for anticoagulation therapy; and
- Have an appropriate rationale to seek a nonpharmacologic alternative to anticoagulation therapy, taking into account the safety and effectiveness of the device compared to anticoagulation therapy.

FDA product code: NGV.

Several other devices are being evaluated for LAA occlusion but are not approved in the U.S. for percutaneous LAAC. In 2006, the Lariat^{TM†} Loop Applicator device (SentreHEART [now AtriCure]), a suture delivery system, was cleared for marketing by the FDA through the 510(k) process. The intended use is to facilitate suture placement and knot tying in surgical applications where soft tissues are being approximated or ligated with a pretied polyester suture. The Amplatzer Cardiac Plug device (St. Jude Medical [now Abbott]) and WaveCrest^{TM†} (Johnson & Johnson Biosense Webster) have CE approval in Europe for LAAC but are not currently approved in the U.S. for this indication.

Rationale/Source

This medical policy was developed through consideration of peer-reviewed medical literature generally recognized by the relevant medical community, U.S. Food and Drug Administration approval status, nationally accepted standards of medical practice and accepted standards of medical practice in this community, technology evaluation centers, reference to regulations, other plan medical policies, and accredited national guidelines.

Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation

Policy # 00296

Original Effective Date: 05/18/2011

Current Effective Date: 08/01/2026

Stroke prevention in patients with atrial fibrillation (AF) is an important goal of treatment. Treatment with anticoagulant medications is the most common approach to stroke prevention. Because most embolic strokes originate from the left atrial appendage, occlusion of the left atrial appendage may offer a nonpharmacologic alternative to anticoagulant medications to lower the risk of stroke. Multiple percutaneously deployed devices are being investigated for left atrial appendage closure (LAAC). Two types of left atrial appendage devices (the Watchman and Amplatzer Amulet devices) have approval from the U.S. Food and Drug Administration (FDA) for stroke prevention in patients with AF.

Summary of Evidence

For individuals who have atrial fibrillation (AF) who are at increased risk for embolic stroke who receive a U.S. Food and Drug Administration (FDA)-approved percutaneous left atrial appendage closure (LAAC) device (e.g., the Watchman or Amulet device), the evidence includes randomized controlled trials (RCTs) and observational studies. Relevant outcomes are overall survival, morbid events, and treatment-related morbidity.

Two initial industry-sponsored RCTs compared the Watchman device with warfarin. The PROTECT AF trial (2009) reported noninferiority of LAAC vs warfarin on a composite outcome of stroke, cardiovascular/unexplained death, or systemic embolism after 2 years of follow-up, with continued benefits with the Watchman device after 4 years of follow-up. FDA concerns were driven by high early procedural complications. The PREVAIL trial (2014) did not demonstrate noninferiority for the same composite outcome but did demonstrate noninferiority of the Watchman device to warfarin for late ischemic stroke and systemic embolization (>7 days post-procedure). FDA approval relied in part on pooled patient-level analyses rather than unequivocal success of individual trials. Patient-level meta-analyses at 5-year follow-up for the 2 Watchman trials reported that the Watchman device is noninferior to warfarin on the composite outcome of stroke, systemic embolism, and cardiovascular death. The Watchman was associated with lower rates of major bleeding, particularly hemorrhagic stroke, and mortality over the long term.

Evidence for the Amplatzer Amulet device comes from 2 RCTs comparing the Amulet and Watchman devices, one of which was a shorter trial that assessed periprocedural outcomes at 45 days and again at 13 months. The second trial comparing the Amulet and Watchman devices found the Amulet device to be noninferior to the Watchman device after 18 months of follow-up for a composite efficacy outcome that included ischemic stroke or systemic embolism and for a composite safety outcome that included all-cause mortality, major bleeding or procedure-related complications. At 3 and 5 year follow-up, clinical outcomes remained similar between patients in the Amulet group and the Watchman group, with a higher percentage of Amulet users not using oral anticoagulation.

PRAGUE-17 RCT evaluated the use of either the Amplatzer Amulet or Watchman device versus anticoagulants; subgroup analyses according to device were not performed. After up to 4 years of follow-up, the study found LAAC with either the Watchman or Amulet was noninferior to anticoagulants for a composite outcome that included stroke, transient ischemic attack (TIA),

Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation

Policy # 00296

Original Effective Date: 05/18/2011

Current Effective Date: 08/01/2026

systemic embolism, clinically significant bleeding, significant periprocedural or device-related complications, or cardiovascular mortality.

The OPTION trial (2024) was an international randomized trial involving 1600 patients with atrial fibrillation who had an elevated score (≥ 2 in men and ≥ 3 in women) on the CHA₂DS₂-VASc scale and who underwent catheter ablation. Patients were randomly assigned in a 1:1 ratio to undergo left atrial appendage closure (N 803) or receive oral anticoagulation (N 797). The primary safety end point, tested for superiority, was non-procedure-related major bleeding or clinically relevant nonmajor bleeding. Procedural bleeding, which is the most common adverse effect of LAAC, was not included in the primary safety endpoint. The primary efficacy end point, tested for noninferiority, was a composite of death from any cause, stroke, or systemic embolism at 36 months. Neither strategy has demonstrated a consistent or reproducible reduction in all-cause mortality in randomized trials; adding an endpoint not affected by either treatment inflates number of events which can make noninferiority easier to reach. Stroke rate was very low in both arms (1.2% and 1.3%); to discern any signal of noninferiority or superiority of the device with very low stroke rate would require much higher number of participants (underpowering). The secondary end point, tested for noninferiority, was major bleeding, including procedure-related bleeding, through 36 months. At 36 months, a primary safety end-point event had occurred in 65 patients (8.5%) in the left atrial appendage closure group (device group) and in 137 patients (18.1%) in the anticoagulation group ($P < 0.001$ for superiority); a primary efficacy end-point event had occurred in 41 patients (5.3%) and 44 patients (5.8%), respectively ($P < 0.001$ for noninferiority); and a secondary end-point event had occurred in 3.9% and 5.0% ($P < 0.001$ for noninferiority). Complications related to the appendage closure device or procedure occurred in 23 patients (3%). One in five patients had incomplete LAA closure with peri device leak.

While earlier warfarin-era trials suggested a potential long-term net clinical benefit of LAAC in select populations, emerging higher-quality randomized evidence in the DOAC (direct oral anticoagulant) era published in 2026 has not consistently demonstrated net health outcome improvement. The CHAMPION-AF trial targeted anticoagulation-eligible AF population and CLOSURE-AF targeted high-bleeding-risk AF population.

The CHAMPION-AF trial (2026) was a large, industry-sponsored, randomized, prospective, international noninferiority trial that compared percutaneous left atrial appendage closure (LAAC) using the Watchman FLX device with non-vitamin K antagonist oral anticoagulant (DOAC) therapy in patients with nonvalvular AF who were *eligible* for long-term anticoagulation. A total of 3,000 patients were randomized 1:1 and followed for a median of 3 years. The study population was moderate risk, with a mean CHA₂DS₂-VASc score of 3.5 and a low mean HAS-BLED score of 1.3. The primary efficacy endpoint was a composite of cardiovascular death, stroke (ischemic or hemorrhagic), or systemic embolism, tested for noninferiority using an absolute noninferiority margin of 4.8 percentage points. At 3 years, the primary endpoint occurred numerically more often in the device group than in the anticoagulation group (5.7% vs 4.8%), meeting the prespecified criterion for noninferiority but not superiority. Stroke events were more frequent in the device group, driven primarily by ischemic stroke (17 more strokes, HR 1.61). The primary safety endpoint, non-

Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation

Policy # 00296

Original Effective Date: 05/18/2011

Current Effective Date: 08/01/2026

procedure-related bleeding, occurred less frequently in the device group compared with the anticoagulation group (10.9% vs 19.0%), demonstrating superiority for bleeding reduction. In contrast, the secondary safety endpoint of procedural plus non-procedural major bleeding showed numerically similar event rates between groups (83 vs 87 events; 5.9% vs 6.4%) and met criteria for noninferiority but not superiority. Procedure-related complications included pericardial effusion requiring intervention (0.7%), device-related thrombus (4.8%), and peri-device leak (21%). Two strokes were attributed to clinically significant device-related thrombus.

There are several design considerations related to the CHAMPION-AF trial. Event rates in both study arms were substantially lower than anticipated, resulting in a relatively wide noninferiority margin that permits a potentially higher *relative* risk of thromboembolic events in the device group. The trial showed numerically higher ischemic stroke in the device arm (absolute +1.1%) and device-related thrombus (around 5%); noninferiority was demonstrated based on the prespecified statistical margin, despite numerically higher ischemic stroke rates and lower-than-anticipated event rates, limiting conclusions regarding clinical equivalence. Additionally, more than two-thirds of participants had paroxysmal atrial fibrillation, and patients with very high stroke risk ($\text{CHA}_2\text{DS}_2\text{-VASc} \geq 5$) were under-represented, limiting generalizability to higher-risk populations. The trial evaluated only one LAAC device and mandated post-implant antithrombotic therapy, which tempers conclusions regarding the ability of LAAC to fully replace anticoagulation in patients otherwise suitable for DOAC therapy.

The CLOSURE-AF trial (2025) was a publicly funded, pragmatic, multicenter randomized controlled trial conducted in Germany that compared catheter-based LAAC using multiple approved devices with physician-directed best medical therapy in patients with atrial fibrillation at high risk of both stroke and bleeding (population that LAAC is most often used for). A total of 888 patients were included in the primary analysis, with a mean age of 77.9 years, a mean $\text{CHA}_2\text{DS}_2\text{-VASc}$ score of 5.2, and a mean HAS-BLED score of 3.0, representing a substantially higher-risk population than that enrolled in CHAMPION-AF.

The primary endpoint was a composite of stroke, systemic embolism, major bleeding, and cardiovascular or unexplained death, tested for noninferiority using a hazard ratio margin of 1.3. After a median follow-up of 3 years, LAAC failed to meet noninferiority criteria compared with medical therapy. Primary endpoint events occurred more frequently in the device group than in the medical-therapy group (16.8 vs 13.3 events per 100 patient-years), and restricted mean survival time favored medical therapy.

No significant reduction in major bleeding was observed with LAAC compared with medical therapy. Bleeding events in the device group were concentrated in the early post-procedural period and were attributed in part to periprocedural complications and post-implant antiplatelet therapy, without evidence of later bleeding reduction compared with medical therapy. Serious adverse events were common in both groups but occurred more frequently in patients undergoing LAAC. Periprocedural complications included pericardial tamponade, device embolization requiring surgical retrieval, and procedure-related mortality. Authors concluded that LAAC was not

Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation

Policy # 00296

Original Effective Date: 05/18/2011

Current Effective Date: 08/01/2026

noninferior to physician-directed best medical care over a 3-year follow-up period. The editorial in NEJM noted that the findings in this trial should have immediate clinical effect as LAAC failed to fulfill its theoretical promise to become an alternative treatment to best medical therapy for AF population, at least for older patients at high risk of stroke and bleeding; best individualized medical therapy should remain standard treatment.

The CLOSURE-AF findings suggest that, in older population with advanced comorbidity and high bleeding risk, LAAC does not confer an overall clinical advantage compared with contemporary medical therapy and may expose patients to early procedural harm without demonstrable net benefit. The pragmatic nature of the trial, inclusion of multiple devices, and use of real-world medical therapy enhance generalizability to routine clinical practice, particularly for patients similar to those currently targeted for LAAC on the basis of bleeding risk.

Taken together, these trials do not demonstrate consistent improvement in net health outcomes with percutaneous LAAC compared with optimal medical therapy, particularly in populations at highest risk of stroke and bleeding. Long-term comparative effectiveness data and more precise identification of patient subgroups most likely to benefit from LAAC are needed to define its appropriate role compared to optimal medical therapy including oral anticoagulation.

For individuals who have AF who are at increased risk for embolic stroke who receive a percutaneous LAAC device other than the Watchman device or Amplatzer Amulet device (eg, Lariat or Amplatzer Cardiac Plug), the evidence includes one RCT, several nonrandomized comparator studies, and uncontrolled observational studies. Relevant outcomes are overall survival, morbid events, and treatment-related morbidity. One RCT with the Lariat device did not find a reduction in atrial arrhythmias when the device was used in combination with pulmonary vein isolation compared with pulmonary vein isolation alone. One nonrandomized study that compared outcomes among patients undergoing LAAC with the Lariat device with patients receiving anticoagulant or antiplatelet therapy reported fewer thromboembolic events in the group receiving the Lariat device. Evidence from other observational studies of these devices report high procedural success but also numerous complications. In addition, these devices do not have FDA approval for LAAC. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

Supplemental Information

Clinical Input From Physician Specialty Societies and Academic Medical Centers

While the various physician specialty societies and academic medical centers may collaborate with and make recommendations during this process, through the provision of appropriate reviewers, input received does not represent an endorsement or position statement by the physician specialty societies or academic medical centers, unless otherwise noted.

Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation

Policy # 00296

Original Effective Date: 05/18/2011

Current Effective Date: 08/01/2026

2015 Input

In response to requests, input was received from 1 physician specialty society (2 responses) and 4 academic medical centers, 1 of which provided 4 responses, for a total of 8 responses, while this policy was under review in 2015. Input generally supported the use of a left atrial appendage closure device approved by the U.S. Food and Drug Administration for patients with an increased risk of stroke and systemic embolism, based on CHADS₂ or CHA₂DS₂-VASc score. Systemic anticoagulation therapy was recommended, but the long-term risks of systemic anticoagulation outweigh the risks of the device implantation.

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American College of Chest Physicians

In 2018, the American College of Chest Physicians (CHEST) guideline made the following recommendation regarding left atrial appendage (LAA) occlusion and oral anticoagulation: "In patients with AF [atrial fibrillation] at high risk of ischemic stroke who have absolute contraindications for OAC [oral anticoagulation], we suggest using LAA occlusion (Weak recommendation, low-quality evidence)."

American Heart Association

In 2019, the American Heart Association (AHA), in collaboration with the American College of Cardiology (ACC) and the Heart Rhythm Society (HRS), published an update of their guideline for the management of patients with AF. A new recommendation in the guideline states: "Percutaneous LAA occlusion may be considered in patients with AF at increased risk of stroke who have contraindications to long-term anticoagulation." The class of recommendation is IIb (weak) and the level of evidence is B_{NR} (moderate quality of evidence, nonrandomized). No other LAA closure (LAAC) devices are mentioned in the guideline. Another guideline update was published in 2023. Based on additional data on safety and efficacy of LAA occlusion devices, the class of recommendation was updated to IIa (moderate) compared to the 2019 recommendation of IIb.

The AHA also released a scientific statement in 2021 about managing AF in patients with heart failure and reduced ejection fraction. They state that, "It is reasonable to consider LAA closure in patients with AF and heart failure with reduced ejection fraction (HFrEF) with moderate to high stroke risk and contraindications to long-term oral anticoagulation", however, they also note that the role of LAA therapies in patients with AF with HFrEF needs to be better understood, and this is an opportunity for future research.

Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation

Policy # 00296

Original Effective Date: 05/18/2011

Current Effective Date: 08/01/2026

Heart Rhythm Society

In collaboration with the Society for Cardiovascular Angiography and Interventions Foundation, the HRS published an expert consensus statement on transcatheter LAAC in 2023. They state that "LAAC is appropriate for patients with nonvalvular atrial fibrillation with high thromboembolic risk who are not suited for long-term oral anticoagulation and who have adequate life expectancy (minimum >1 year) and quality of life to benefit from LAAC."

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

Since 2016, the Centers for Medicare & Medicaid Services has a national coverage determination under coverage with evidence development for percutaneous LAAC in AF, as follows:

"LAAC devices are covered when the device has received U.S. Food and Drug Administration (FDA) Premarket Approval (PMA) for that device's FDA-approved indication and meet all of the conditions specified below:

The patient must have:

- A CHADS₂ score ≥ 2 (Congestive heart failure, Hypertension, Age > 75, Diabetes, Stroke/transient ischemia attack/thromboembolism) or CHA₂DS₂-VASc score ≥ 3 (Congestive heart failure, Hypertension, Age ≥ 65 , Diabetes, Stroke/transient ischemia attack/thromboembolism, Vascular disease, Sex category).
- A formal shared decision making interaction with an independent non-interventional physician using an evidence-based decision tool on oral anticoagulation in patients with NVAf [nonvalvular atrial fibrillation] prior to LAAC. Additionally, the shared decision making interaction must be documented in the medical record.
- A suitability for short-term warfarin but deemed unable to take long-term oral anticoagulation following the conclusion of shared decision making, as LAAC is only covered as a second line therapy to oral anticoagulants. The patient (preoperatively and postoperatively) is under the care of a cohesive, multidisciplinary team (MDT) of medical professionals. The procedure must be furnished in a hospital with an established structural heart disease (SHD) and/or electrophysiology (EP) program.

The procedure must be performed by an interventional cardiologist(s), electrophysiologist(s), or cardiovascular surgeon(s) that meet the following criteria:

- Has received training prescribed by the manufacturer on the safe and effective use of the device prior to performing LAAC; and,
- Has performed ≥ 25 interventional cardiac procedures that involve transseptal puncture through an intact septum; and,
- Continues to perform ≥ 25 interventional cardiac procedures that involve transseptal puncture through an intact septum, of which at least 12 are LAAC, over a 2-year period."

Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation

Policy # 00296

Original Effective Date: 05/18/2011

Current Effective Date: 08/01/2026

Patients must be enrolled in approved registries that track outcomes for procedures and devices.

Ongoing and Unpublished Clinical Trials

Some currently ongoing and unpublished trials that might influence this policy are listed in Table 2.

Table 2. Summary of Key Trials

NCT No.	Trial Name	Planned Enrollment	Completion Date
<i>Ongoing</i>			
NCT06686485	Concomitant Left Atrial Appendage Closure and Pulsed Field Ablation-Asia	733	Oct 2029
NCT06465706	A Prospective, Multicenter, Randomized Controlled Trial Assessing the Safety and Efficacy of the LAMPRE™ Plus Left Atrial Appendage Closure System to REDUCE the Risk of Thromboembolism in Patients With Non-Valvular Atrial Fibrillation	1826	Jan 2030
NCT06861673	Concomitant Pulse Field Ablation Based pulmonary Vein Isolation and left Atrial Appendage Closure - The COCONUT Study	60	Dec 2026
NCT03309332 ^a	OSB Lead-AMPLATZER PFO Occluder New Enrollment PAS	1214	Feb 2030
NCT04394546 ^a	WATCHMAN FLX Versus NOAC for Embolic Protection in the Management of Patients With Non-Valvular Atrial Fibrillation	3000	Dec 2027
NCT04226547 ^a	Clinical Trial of Atrial Fibrillation Patients Comparing Left Atrial Appendage Occlusion Therapy to Non-vitamin K Antagonist Oral Anticoagulants	2650	Aug 2030
<i>Unpublished</i>			
NCT03463317	Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation at High Risk of Stroke and Bleeding Compared to Medical Therapy: a Prospective Randomized Clinical Trial	912	Nov 2024
NCT03276169	Left Atrial Function Changes after Left Atrial Appendage Closure in Patients with Persistent Atrial Fibrillation	105	Nov 2020 (updated Mar 2021)

Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation

Policy # 00296

Original Effective Date: 05/18/2011

Current Effective Date: 08/01/2026

NCT No.	Trial Name	Planned Enrollment	Completion Date
NCT01118299 ^a	AMPLATZER Cardiac Plug Clinical Trial	97 (actual; study terminated)	Dec 2018 (updated Apr 2020)
NCT02681042	Left Atrial Appendage Closure with SentreHeart Lariat Device	9	May 2018 (updated Feb 2021)

NCT: national clinical trial.

^a indicates industry-sponsored study.

References

1. Mou L, Norby FL, Chen LY, et al. Lifetime Risk of Atrial Fibrillation by Race and Socioeconomic Status: ARIC Study (Atherosclerosis Risk in Communities). *Circ Arrhythm Electrophysiol*. Jul 2018; 11(7): e006350. PMID 30002066
2. Dewland TA, Olgin JE, Vittinghoff E, et al. Incident atrial fibrillation among Asians, Hispanics, blacks, and whites. *Circulation*. Dec 03 2013; 128(23): 2470-7. PMID 24103419
3. Gardener H, Sacco RL, Rundek T, et al. Race and Ethnic Disparities in Stroke Incidence in the Northern Manhattan Study. *Stroke*. Apr 2020; 51(4): 1064-1069. PMID 32078475
4. Guo J, Gabriel N, Magnani JW, et al. Racial and Urban-Rural Difference in the Frequency of Ischemic Stroke as Initial Manifestation of Atrial Fibrillation. *Front Public Health*. 2021; 9: 780185. PMID 34805085
5. Lip GYH, Banerjee A, Boriani G, et al. Antithrombotic Therapy for Atrial Fibrillation: CHEST Guideline and Expert Panel Report. *Chest*. Nov 2018; 154(5): 1121-1201. PMID 30144419
6. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the Heart Rhythm Society. *J Am Coll Cardiol*. Dec 02 2014; 64(21): e1-76. PMID 24685669
7. Lip GY, Frison L, Halperin JL, et al. Comparative validation of a novel risk score for predicting bleeding risk in anticoagulated patients with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile INR, Elderly, Drugs/Alcohol Concomitantly) score. *J Am Coll Cardiol*. Jan 11 2011; 57(2): 173-80. PMID 21111555
8. Food and Drug Administration. Summary of Safety and Effectiveness Data. WATCHMAN Left Atrial Appendage Closure Device with Delivery System and WATCHMAN FLX Left Atrial Appendage Closure Device with Delivery System. https://www.accessdata.fda.gov/cdrh_docs/pdf13/P130013S035B.pdf.
9. Food and Drug Administration. Approval Letter: Amplatzer Amulet Left Atrial Appendage Occluder; 2021. https://www.accessdata.fda.gov/cdrh_docs/pdf20/P200049A.pdf.
10. Food and Drug Administration. Left Atrial Appendage Occlusion (LAAO) Devices Potentially Associated with Procedural Outcome Differences Between Women and Men: Letter to Health

Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation

Policy # 00296

Original Effective Date: 05/18/2011

Current Effective Date: 08/01/2026

- Care Providers. <https://public4.pagefreezer.com/browse/FDA/28-09-2021T17:30/https://www.fda.gov/medical-devices/letters-health-care-providers/left-atrial-appendage-occlusion-laa-devices-potentially-associated-procedural-outcome-differences>.
11. Darden D, Duong T, Du C, et al. Sex Differences in Procedural Outcomes Among Patients Undergoing Left Atrial Appendage Occlusion: Insights From the NCDR LAAO Registry. *JAMA Cardiol.* Nov 01 2021; 6(11): 1275-1284. PMID 34379072
 12. Food and Drug Administration. Approval Letter: WATCHMAN LAA Closure Technology. 2015; http://www.accessdata.fda.gov/cdrh_docs/pdf13/p130013a.pdf.
 13. Reddy VY, Doshi SK, Kar S, et al. 5-Year Outcomes After Left Atrial Appendage Closure: From the PREVAIL and PROTECT AF Trials. *J Am Coll Cardiol.* Dec 19 2017; 70(24): 2964-2975. PMID 29103847
 14. Bode WD, Patel N, Gehi AK. Left atrial appendage occlusion for prevention of stroke in nonvalvular atrial fibrillation: a meta-analysis. *J Interv Card Electrophysiol.* Jun 2015; 43(1): 79-89. PMID 25711953
 15. Briceno DF, Villablanca P, Cyrille N, et al. Left Atrial Appendage Occlusion Device and Novel Oral Anticoagulants Versus Warfarin for Stroke Prevention in Nonvalvular Atrial Fibrillation: Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Circ Arrhythm Electrophysiol.* Oct 2015; 8(5): 1057-64. PMID 26226997
 16. Holmes DR, Doshi SK, Kar S, et al. Left Atrial Appendage Closure as an Alternative to Warfarin for Stroke Prevention in Atrial Fibrillation: A Patient-Level Meta-Analysis. *J Am Coll Cardiol.* Jun 23 2015; 65(24): 2614-2623. PMID 26088300
 17. Li X, Wen SN, Li SN, et al. Over 1-year efficacy and safety of left atrial appendage occlusion versus novel oral anticoagulants for stroke prevention in atrial fibrillation: A systematic review and meta-analysis of randomized controlled trials and observational studies. *Heart Rhythm.* Jun 2016; 13(6): 1203-14. PMID 26724488
 18. Lip GY, Lane DA. Stroke prevention in atrial fibrillation: a systematic review. *JAMA.* May 19 2015; 313(19): 1950-62. PMID 25988464
 19. Price MJ, Reddy VY, Valderrábano M, et al. Bleeding Outcomes After Left Atrial Appendage Closure Compared With Long-Term Warfarin: A Pooled, Patient-Level Analysis of the WATCHMAN Randomized Trial Experience. *JACC Cardiovasc Interv.* Dec 28 2015; 8(15): 1925-1932. PMID 26627989
 20. Noelck N, Papak J, Freeman M, et al. Effectiveness of Left Atrial Appendage Exclusion Procedures to Reduce the Risk of Stroke: A Systematic Review of the Evidence. *Circ Cardiovasc Qual Outcomes.* Jul 2016; 9(4): 395-405. PMID 27407055
 21. Sahay S, Nombela-Franco L, Rodes-Cabau J, et al. Efficacy and safety of left atrial appendage closure versus medical treatment in atrial fibrillation: a network meta-analysis from randomised trials. *Heart.* Jan 15 2017; 103(2): 139-147. PMID 27587437
 22. Oliva A, Ioppolo AM, Chiarito M, et al. Left Atrial Appendage Closure Compared With Oral Anticoagulants for Patients With Atrial Fibrillation: A Systematic Review and Network Meta-Analysis. *J Am Heart Assoc.* Aug 20 2024; 13(16): e034815. PMID 39119987
 23. Wei Z, Zhang X, Wu H, et al. A meta-analysis for efficacy and safety evaluation of transcatheter left atrial appendage occlusion in patients with nonvalvular atrial fibrillation. *Medicine (Baltimore).* Aug 2016; 95(31): e4382. PMID 27495048

Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation

Policy # 00296

Original Effective Date: 05/18/2011

Current Effective Date: 08/01/2026

24. Tereshchenko LG, Henrikson CA, Cigarroa J, et al. Comparative Effectiveness of Interventions for Stroke Prevention in Atrial Fibrillation: A Network Meta-Analysis. *J Am Heart Assoc.* May 20 2016; 5(5). PMID 27207998
25. Bajaj NS, Kalra R, Patel N, et al. Comparison of Approaches for Stroke Prophylaxis in Patients with Non-Valvular Atrial Fibrillation: Network Meta-Analyses of Randomized Controlled Trials. *PLoS One.* 2016; 11(10): e0163608. PMID 27706224
26. Hanif H, Belley-Cote EP, Alotaibi A, et al. Left atrial appendage occlusion for stroke prevention in patients with atrial fibrillation: a systematic review and network meta-analysis of randomized controlled trials. *J Cardiovasc Surg (Torino).* Feb 2018; 59(1): 128-139. PMID 28215062
27. Holmes DR, Reddy VY, Turi ZG, et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. *Lancet.* Aug 15 2009; 374(9689): 534-42. PMID 19683639
28. Reddy VY, Doshi SK, Sievert H, et al. Percutaneous left atrial appendage closure for stroke prophylaxis in patients with atrial fibrillation: 2.3-Year Follow-up of the PROTECT AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients with Atrial Fibrillation) Trial. *Circulation.* Feb 12 2013; 127(6): 720-9. PMID 23325525
29. Reddy VY, Sievert H, Halperin J, et al. Percutaneous left atrial appendage closure vs warfarin for atrial fibrillation: a randomized clinical trial. *JAMA.* Nov 19 2014; 312(19): 1988-98. PMID 25399274
30. Alli O, Doshi S, Kar S, et al. Quality of life assessment in the randomized PROTECT AF (Percutaneous Closure of the Left Atrial Appendage Versus Warfarin Therapy for Prevention of Stroke in Patients With Atrial Fibrillation) trial of patients at risk for stroke with nonvalvular atrial fibrillation. *J Am Coll Cardiol.* Apr 30 2013; 61(17): 1790-8. PMID 23500276
31. Holmes DR, Kar S, Price MJ, et al. Prospective randomized evaluation of the Watchman Left Atrial Appendage Closure device in patients with atrial fibrillation versus long-term warfarin therapy: the PREVAIL trial. *J Am Coll Cardiol.* Jul 08 2014; 64(1): 1-12. PMID 24998121
32. Osmancik P, Herman D, Neuzil P, et al. Left Atrial Appendage Closure Versus Direct Oral Anticoagulants in High-Risk Patients With Atrial Fibrillation. *J Am Coll Cardiol.* Jun 30 2020; 75(25): 3122-3135. PMID 32586585
33. Osmancik P, Herman D, Neuzil P, et al. 4-Year Outcomes After Left Atrial Appendage Closure Versus Nonwarfarin Oral Anticoagulation for Atrial Fibrillation. *J Am Coll Cardiol.* Jan 04 2022; 79(1): 1-14. PMID 34748929
34. Wazni OM, Saliba WI, Nair DG, et al. Left Atrial Appendage Closure after Ablation for Atrial Fibrillation. *N Engl J Med.* Apr 03 2025; 392(13): 1277-1287. PMID 39555822
35. Lam YY, Yip GW, Yu CM, et al. Left atrial appendage closure with AMPLATZER cardiac plug for stroke prevention in atrial fibrillation: initial Asia-Pacific experience. *Catheter Cardiovasc Interv.* Apr 01 2012; 79(5): 794-800. PMID 21542102
36. Montenegro MJ, Quintella EF, Damonte A, et al. Percutaneous occlusion of left atrial appendage with the Amplatzer Cardiac PlugTM in atrial fibrillation. *Arq Bras Cardiol.* Feb 2012; 98(2): 143-50. PMID 22286325
37. Park JW, Bethencourt A, Sievert H, et al. Left atrial appendage closure with Amplatzer cardiac plug in atrial fibrillation: initial European experience. *Catheter Cardiovasc Interv.* Apr 01 2011; 77(5): 700-6. PMID 20824765

Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation

Policy # 00296

Original Effective Date: 05/18/2011

Current Effective Date: 08/01/2026

38. Reddy VY, Holmes D, Doshi SK, et al. Safety of percutaneous left atrial appendage closure: results from the Watchman Left Atrial Appendage System for Embolic Protection in Patients with AF (PROTECT AF) clinical trial and the Continued Access Registry. *Circulation*. Feb 01 2011; 123(4): 417-24. PMID 21242484
39. Swaans MJ, Post MC, Rensing BJ, et al. Percutaneous left atrial appendage closure for stroke prevention in atrial fibrillation. *Neth Heart J*. Apr 2012; 20(4): 161-6. PMID 22231152
40. Reddy VY, Möbius-Winkler S, Miller MA, et al. Left atrial appendage closure with the Watchman device in patients with a contraindication for oral anticoagulation: the ASAP study (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology). *J Am Coll Cardiol*. Jun 25 2013; 61(25): 2551-6. PMID 23583249
41. Boersma LV, Schmidt B, Betts TR, et al. Implant success and safety of left atrial appendage closure with the WATCHMAN device: peri-procedural outcomes from the EWOLUTION registry. *Eur Heart J*. Aug 2016; 37(31): 2465-74. PMID 26822918
42. Dukkipati SR, Kar S, Holmes DR, et al. Device-Related Thrombus After Left Atrial Appendage Closure: Incidence, Predictors, and Outcomes. *Circulation*. Aug 28 2018; 138(9): 874-885. PMID 29752398
43. Jazayeri MA, Vuddanda V, Turagam MK, et al. Safety profiles of percutaneous left atrial appendage closure devices: An analysis of the Food and Drug Administration Manufacturer and User Facility Device Experience (MAUDE) database from 2009 to 2016. *J Cardiovasc Electrophysiol*. Jan 2018; 29(1): 5-13. PMID 28988455
44. Lakkireddy D, Thaler D, Ellis CR, et al. Amplatzer Amulet Left Atrial Appendage Occluder Versus Watchman Device for Stroke Prophylaxis (Amulet IDE): A Randomized, Controlled Trial. *Circulation*. Nov 09 2021; 144(19): 1543-1552. PMID 34459659
45. Galea R, De Marco F, Meneveau N, et al. Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: Primary Results of the SWISS-APERO Randomized Clinical Trial. *Circulation*. Mar 08 2022; 145(10): 724-738. PMID 34747186
46. Galea R, Meneveau N, De Marco F, et al. One-Year Outcomes After Amulet or Watchman Device for Percutaneous Left Atrial Appendage Closure: A Prespecified Analysis of the SWISS-APERO Randomized Clinical Trial. *Circulation*. Feb 06 2024; 149(6): 484-486. PMID 37875064
47. Lakkireddy D, Thaler D, Ellis CR, et al. 3-Year Outcomes From the Amplatzer Amulet Left Atrial Appendage Occluder Randomized Controlled Trial (Amulet IDE). *JACC Cardiovasc Interv*. Aug 14 2023; 16(15): 1902-1913. PMID 37587599
48. Lakkireddy D, Ellis CR, Thaler D, et al. 5-Year Results From the AMPLATZER Amulet Left Atrial Appendage Occluder Randomized Controlled Trial. *J Am Coll Cardiol*. Mar 25 2025; 85(11): 1141-1153. PMID 39570242
49. Landmesser U, Schmidt B, Nielsen-Kudsk JE, et al. Left atrial appendage occlusion with the AMPLATZER Amulet device: periprocedural and early clinical/echocardiographic data from a global prospective observational study. *EuroIntervention*. Sep 20 2017; 13(7): 867-876. PMID 28649053
50. Landmesser U, Tondo C, Camm J, et al. Left atrial appendage occlusion with the AMPLATZER Amulet device: one-year follow-up from the prospective global Amulet observational registry. *EuroIntervention*. Aug 03 2018; 14(5): e590-e597. PMID 29806820

Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation

Policy # 00296

Original Effective Date: 05/18/2011

Current Effective Date: 08/01/2026

51. Hildick-Smith D, Landmesser U, Camm AJ, et al. Left atrial appendage occlusion with the Amplatzer™ Amulet™ device: full results of the prospective global observational study. *Eur Heart J*. Aug 07 2020; 41(30): 2894-2901. PMID 32243499
52. Nielsen-Kudsk JE, Korsholm K, Damgaard D, et al. Clinical Outcomes Associated With Left Atrial Appendage Occlusion Versus Direct Oral Anticoagulation in Atrial Fibrillation. *JACC Cardiovasc Interv*. Jan 11 2021; 14(1): 69-78. PMID 33413867
53. Chatterjee S, Herrmann HC, Wilensky RL, et al. Safety and Procedural Success of Left Atrial Appendage Exclusion With the Lariat Device: A Systematic Review of Published Reports and Analytic Review of the FDA MAUDE Database. *JAMA Intern Med*. Jul 2015; 175(7): 1104-9. PMID 25938303
54. Price MJ, Gibson DN, Yakubov SJ, et al. Early safety and efficacy of percutaneous left atrial appendage suture ligation: results from the U.S. transcatheter LAA ligation consortium. *J Am Coll Cardiol*. Aug 12 2014; 64(6): 565-72. PMID 25104525
55. Bartus K, Han FT, Bednarek J, et al. Percutaneous left atrial appendage suture ligation using the LARIAT device in patients with atrial fibrillation: initial clinical experience. *J Am Coll Cardiol*. Jul 09 2013; 62(2): 108-118. PMID 23062528
56. Massumi A, Chelu MG, Nazeri A, et al. Initial experience with a novel percutaneous left atrial appendage exclusion device in patients with atrial fibrillation, increased stroke risk, and contraindications to anticoagulation. *Am J Cardiol*. Mar 15 2013; 111(6): 869-73. PMID 23312129
57. Miller MA, Gangireddy SR, Doshi SK, et al. Multicenter study on acute and long-term safety and efficacy of percutaneous left atrial appendage closure using an epicardial suture snaring device. *Heart Rhythm*. Nov 2014; 11(11): 1853-9. PMID 25068574
58. Gafoor S, Franke J, Bertog S, et al. Left atrial appendage occlusion in octogenarians: short-term and 1-year follow-up. *Catheter Cardiovasc Interv*. Apr 01 2014; 83(5): 805-10. PMID 24259397
59. Lakkireddy DR, Wilber DJ, Mittal S, et al. Pulmonary Vein Isolation With or Without Left Atrial Appendage Ligation in Atrial Fibrillation: The aMAZE Randomized Clinical Trial. *JAMA*. Apr 02 2024; 331(13): 1099-1108. PMID 38563835
60. Lakkireddy D, Afzal MR, Lee RJ, et al. Short and long-term outcomes of percutaneous left atrial appendage suture ligation: Results from a US multicenter evaluation. *Heart Rhythm*. May 2016; 13(5): 1030-1036. PMID 26872554
61. Bartus K, Bednarek J, Myc J, et al. Feasibility of closed-chest ligation of the left atrial appendage in humans. *Heart Rhythm*. Feb 2011; 8(2): 188-93. PMID 21050893
62. Stone D, Byrne T, Pershad A. Early results with the LARIAT device for left atrial appendage exclusion in patients with atrial fibrillation at high risk for stroke and anticoagulation. *Catheter Cardiovasc Interv*. Jul 2015; 86(1): 121-7. PMID 23765504
63. Fink T, Schlüter M, Tilz RR, et al. Acute and long-term outcomes of epicardial left atrial appendage ligation with the second-generation LARIAT device: a high-volume electrophysiology center experience. *Clin Res Cardiol*. Dec 2018; 107(12): 1139-1147. PMID 29881879
64. Dar T, Afzal MR, Yarlagadda B, et al. Mechanical function of the left atrium is improved with epicardial ligation of the left atrial appendage: Insights from the LAFIT-LARIAT Registry. *Heart Rhythm*. Jul 2018; 15(7): 955-959. PMID 29477973

Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation

Policy # 00296

Original Effective Date: 05/18/2011

Current Effective Date: 08/01/2026

65. Litwinowicz R, Bartus M, Burysz M, et al. Long term outcomes after left atrial appendage closure with the LARIAT device-Stroke risk reduction over five years follow-up. *PLoS One*. 2018; 13(12): e0208710. PMID 30566961
66. Litwinowicz R, Bartus M, Malec-Litwinowicz M, et al. Left Atrial Appendage Occlusion for Secondary Stroke Prevention in Patients with Atrial Fibrillation: Long-Term Results. *Cerebrovasc Dis*. 2019; 47(3-4): 188-195. PMID 31121584
67. Litwinowicz R, Bartus M, Kapelak B, et al. Reduction in risk of stroke and bleeding after left atrial appendage closure with LARIAT device in patients with increased risk of stroke and bleeding: Long term results. *Catheter Cardiovasc Interv*. Nov 15 2019; 94(6): 837-842. PMID 30884101
68. Nietlispach F, Gloekler S, Krause R, et al. Amplatzer left atrial appendage occlusion: single center 10-year experience. *Catheter Cardiovasc Interv*. Aug 01 2013; 82(2): 283-9. PMID 23412815
69. Kefer J, Vermeersch P, Budts W, et al. Transcatheter left atrial appendage closure for stroke prevention in atrial fibrillation with Amplatzer cardiac plug: the Belgian Registry. *Acta Cardiol*. Dec 2013; 68(6): 551-8. PMID 24579432
70. Guérios EE, Schmid M, Gloekler S, et al. Left atrial appendage closure with the Amplatzer cardiac plug in patients with atrial fibrillation. *Arq Bras Cardiol*. Jun 2012; 98(6): 528-36. PMID 22584492
71. Danna P, Proietti R, Sagone A, et al. Does left atrial appendage closure with a cardiac plug system reduce the stroke risk in nonvalvular atrial fibrillation patients? A single-center case series. *Pacing Clin Electrophysiol*. Mar 2013; 36(3): 347-53. PMID 23252940
72. Lopez-Minguez JR, Eldoayen-Gragera J, Gonzalez-Fernandez R, et al. Immediate and one-year results in 35 consecutive patients after closure of left atrial appendage with the Amplatzer Cardiac Plug. *Rev Esp Cardiol*. Feb 2013; 66(2): 90-97. PMID 22939161
73. Streb W, Szymała M, Kukulski T, et al. Percutaneous closure of the left atrial appendage using the Amplatzer Cardiac Plug in patients with atrial fibrillation: evaluation of safety and feasibility. *Kardiol Pol*. 2013; 71(1): 8-16. PMID 23348528
74. Cruz-González I, González-Ferreiro R, Freixa X, et al. Left atrial appendage occlusion for stroke despite oral anticoagulation (resistant stroke). Results from the Amplatzer Cardiac Plug registry. *Rev Esp Cardiol (Engl Ed)*. Jan 2020; 73(1): 28-34. PMID 31036510
75. Santoro G, Meucci F, Stolcova M, et al. Percutaneous left atrial appendage occlusion in patients with non-valvular atrial fibrillation: implantation and up to four years follow-up of the AMPLATZER Cardiac Plug. *EuroIntervention*. Feb 2016; 11(10): 1188-94. PMID 25354761
76. Meerkink D, Butnaru A, Dratva D, et al. Early safety of the Amplatzer Cardiac Plug™ for left atrial appendage occlusion. *Int J Cardiol*. Oct 09 2013; 168(4): 3920-5. PMID 23890886
77. Wiebe J, Bertog S, Franke J, et al. Safety of percutaneous left atrial appendage closure with the Amplatzer cardiac plug in patients with atrial fibrillation and contraindications to anticoagulation. *Catheter Cardiovasc Interv*. Apr 01 2014; 83(5): 796-802. PMID 24327462
78. Urena M, Rodés-Cabau J, Freixa X, et al. Percutaneous left atrial appendage closure with the AMPLATZER cardiac plug device in patients with nonvalvular atrial fibrillation and contraindications to anticoagulation therapy. *J Am Coll Cardiol*. Jul 09 2013; 62(2): 96-102. PMID 23665098

Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation

Policy # 00296

Original Effective Date: 05/18/2011

Current Effective Date: 08/01/2026

79. Gloekler S, Shakir S, Doblies J, et al. Early results of first versus second generation Amplatzer occluders for left atrial appendage closure in patients with atrial fibrillation. Clin Res Cardiol. Aug 2015; 104(8): 656-65. PMID 25736061
80. January CT, Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. Heart Rhythm. Aug 2019; 16(8): e66-e93. PMID 30703530
81. Joglar JA, Chung MK, Armbruster AL, et al. 2023 ACC/AHA/ACCP/HRS Guideline for the Diagnosis and Management of Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. Jan 02 2024; 149(1): e1-e156. PMID 38033089
82. Gopinathannair R, Chen LY, Chung MK, et al. Managing Atrial Fibrillation in Patients With Heart Failure and Reduced Ejection Fraction: A Scientific Statement From the American Heart Association. Circ Arrhythm Electrophysiol. Jun 2021; 14(6): HAE0000000000000078. PMID 34129347
83. Saw J, Holmes DR, Cavalcante JL, et al. SCAI/HRS expert consensus statement on transcatheter left atrial appendage closure. Heart Rhythm. May 2023; 20(5): e1-e16. PMID 36990925
84. Center for Medicare & Medicaid Services. National Coverage Determination (NCD) for Percutaneous Left Atrial Appendage Closure (LAAC) (20.34). 2016; <https://www.cms.gov/medicare-coverage-database/details/ncd-details.aspx?NCDId=367&ncdver=1&NCAId=281&bc=AAAAAAAAACAAAAA%3d%3d&>.
85. Oussama M. Wazni M.D., et al. The New England Journal of Medicine. Left Atrial Appendage Closure after Ablation for Atrial Fibrillation. Published November 16, 2024 N Engl J Med 2025;392:1277-1287 DOI: 10.1056/NEJMoa2408308VOL. 392 NO. 13
86. S.K. Doshi, et al. The New England Journal of Medicine. Left Atrial Appendage Closure or Anticoagulation for Atrial Fibrillation. Abstract.
87. U. Landmesser, et al. The New England Journal of Medicine. Left Atrial Appendage Closure or Medical Therapy in Atrial Fibrillation. Abstract.
88. Petr Widimský, M.D., et al. The New England Journal of Medicine. Left Atrial Appendage Closure — Another Overused Method in Cardiology? Editorial.

Policy History

Original Effective Date: 05/18/2011

Current Effective Date: 08/01/2026

05/05/2011	Medical Policy Committee review
05/18/2011	Medical Policy Implementation Committee approval. New policy.
05/03/2012	Medical Policy Committee review
05/16/2012	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
05/02/2013	Medical Policy Committee review

Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation

Policy # 00296

Original Effective Date: 05/18/2011

Current Effective Date: 08/01/2026

05/22/2013	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
05/01/2014	Medical Policy Committee review
05/21/2014	Medical Policy Implementation Committee approval. Percutaneous added to the title and coverage statement.
06/04/2015	Medical Policy Committee review
06/17/2015	Medical Policy Implementation Committee approval. No change to coverage.
04/07/2016	Medical Policy Committee review
04/20/2016	Medical Policy Implementation Committee approval. An FDA-approved left atrial appendage closure device is considered medically necessary with conditions.
01/01/2017	Coding update: Removing ICD-9 Diagnosis Codes and CPT Coding Update
04/06/2017	Medical Policy Committee review
04/19/2017	Medical Policy Implementation Committee approval. No change to coverage.
06/07/2018	Medical Policy Committee review
06/20/2018	Medical Policy Implementation Committee approval. No change to coverage.
10/04/2018	Medical Policy Committee review
10/17/2018	Medical Policy Implementation Committee approval. Added policy guidelines
10/03/2019	Medical Policy Committee review
10/09/2019	Medical Policy Implementation Committee approval. No change to coverage.
10/01/2020	Medical Policy Committee review
10/07/2020	Medical Policy Implementation Committee approval. Added to policy guideline section.
10/07/2021	Medical Policy Committee review
10/13/2021	Medical Policy Implementation Committee approval. No change to coverage.
08/04/2022	Medical Policy Committee review
08/10/2022	Medical Policy Implementation Committee approval. Policy statements updated to include the FDA-approved Amplatzer Amulet device.
08/03/2023	Medical Policy Committee review
08/09/2023	Medical Policy Implementation Committee approval. No change to coverage.
08/01/2024	Medical Policy Committee review
08/14/2024	Medical Policy Implementation Committee approval. No change to coverage.
08/07/2025	Medical Policy Committee review
08/13/2025	Medical Policy Implementation Committee approval. Coverage eligibility unchanged.
05/07/2026	Medical Policy Committee review
05/13/2026	Medical Policy Implementation Committee review.
06/18/2026	Medical Quality Management Committee approval. Coverage changed from eligible for coverage to Investigational. Added “Based on review of available data, the Company considers the use of devices for percutaneous left atrial appendage closure (e.g., Watchman, Amplatzer Amulet, Lariat® [†] , Amplatzer Cardiac Plug) TM [‡] for the prevention of stroke in individuals with atrial fibrillation (AF) to be investigational.”

Next Scheduled Review Date: 05/2027

Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation

Policy # 00296

Original Effective Date: 05/18/2011

Current Effective Date: 08/01/2026

Coding

The five character codes included in the Louisiana Blue Medical Policy Coverage Guidelines are obtained from Current Procedural Terminology (CPT®), copyright 2025 by the American Medical Association (AMA). CPT is developed by the AMA as a listing of descriptive terms and five character identifying codes and modifiers for reporting medical services and procedures performed by physician.*

The responsibility for the content of Louisiana Blue Medical Policy Coverage Guidelines is with Louisiana Blue and no endorsement by the AMA is intended or should be implied. The AMA disclaims responsibility for any consequences or liability attributable or related to any use, nonuse or interpretation of information contained in Louisiana Blue Medical Policy Coverage Guidelines. Fee schedules, relative value units, conversion factors and/or related components are not assigned by the AMA, are not part of CPT, and the AMA is not recommending their use. The AMA does not directly or indirectly practice medicine or dispense medical services. The AMA assumes no liability for data contained or not contained herein. Any use of CPT outside of Louisiana Blue Medical Policy Coverage Guidelines should refer to the most current Current Procedural Terminology which contains the complete and most current listing of CPT codes and descriptive terms. Applicable FARS/DFARS apply.

CPT is a registered trademark of the American Medical Association.

Codes used to identify services associated with this policy may include (but may not be limited to) the following:

Code Type	Code
CPT	33340
HCPCS	No codes
ICD-10 Diagnosis	All related diagnoses

*Investigational – A medical treatment, procedure, drug, device, or biological product is Investigational if the effectiveness has not been clearly tested and it has not been incorporated into standard medical practice. Any determination we make that a medical treatment, procedure, drug, device, or biological product is Investigational will be based on a consideration of the following:

- A. Whether the medical treatment, procedure, drug, device, or biological product can be lawfully marketed without approval of the U.S. Food and Drug Administration (FDA) and whether such approval has been granted at the time the medical treatment, procedure, drug, device, or biological product is sought to be furnished; or
- B. Whether the medical treatment, procedure, drug, device, or biological product requires further studies or clinical trials to determine its maximum tolerated dose, toxicity, safety, effectiveness, or effectiveness as compared with the standard means of treatment or diagnosis, must improve health outcomes, according to the consensus of opinion among experts as shown by reliable evidence, including:

Percutaneous Left-Atrial Appendage Closure Devices for Stroke Prevention in Atrial Fibrillation

Policy # 00296

Original Effective Date: 05/18/2011

Current Effective Date: 08/01/2026

1. Consultation with technology evaluation center(s);
2. Credible scientific evidence published in peer-reviewed medical literature generally recognized by the relevant medical community; or
3. Reference to federal regulations.

‡ Indicated trademarks are the registered trademarks of their respective owners.

NOTICE: If the Patient's health insurance contract contains language that differs from the BCBSLA Medical Policy definition noted above, the definition in the health insurance contract will be relied upon for specific coverage determinations.

NOTICE: Medical Policies are scientific based opinions, provided solely for coverage and informational purposes. Medical Policies should not be construed to suggest that the Company recommends, advocates, requires, encourages, or discourages any particular treatment, procedure, or service, or any particular course of treatment, procedure, or service.

NOTICE: Federal and State law, as well as contract language, including definitions and specific contract provisions/exclusions, take precedence over Medical Policy and must be considered first in determining eligibility for coverage.

NOTICE: If an authorization for an ongoing course of treatment has been provided to a member and the member changes from one health plan to another health plan (e.g., a member moves from carrier A to Louisiana Blue), Louisiana Blue may honor the previous health plan's authorization for the same service under the same type of in-network benefit for a 90-day transition period. Documentation of the authorization for the ongoing course of treatment from the previous health plan must be provided to us by the member or their provider and the services provided for the course of treatment must otherwise be a covered service under the Louisiana Blue health plan. This provision does not apply to medications covered under the plan's pharmacy benefit.